Mizuho Medy Co.,Ltd. (4595.T)
JPY 1482.0
(-0.47%)
JPY 1482.0
(-0.47%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.77 Billion JPY | -51.85% |
| 2022 | 7.83 Billion JPY | 62.73% |
| 2021 | 4.81 Billion JPY | 1472.33% |
| 2020 | 306.34 Million JPY | -64.96% |
| 2019 | 874.34 Million JPY | -4.88% |
| 2018 | 919.2 Million JPY | 39.26% |
| 2017 | 660.04 Million JPY | 67.01% |
| 2016 | 395.2 Million JPY | 53.42% |
| 2015 | 257.6 Million JPY | -18.81% |
| 2014 | 317.29 Million JPY | 128.27% |
| 2013 | 139 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 519 Million JPY | -46.49% |
| 2024 Q1 | 970 Million JPY | 2.47% |
| 2023 Q4 | 946.61 Million JPY | -30.71% |
| 2023 Q2 | 715.09 Million JPY | -4.14% |
| 2023 Q3 | 1.36 Billion JPY | 91.04% |
| 2023 FY | 3.77 Billion JPY | -51.85% |
| 2023 Q1 | 746 Million JPY | -56.26% |
| 2022 Q2 | 1.28 Billion JPY | -32.88% |
| 2022 Q3 | 2.92 Billion JPY | 127.63% |
| 2022 Q4 | 1.7 Billion JPY | -41.77% |
| 2022 FY | 7.83 Billion JPY | 62.73% |
| 2022 Q1 | 1.91 Billion JPY | 160.66% |
| 2021 Q4 | 735.45 Million JPY | -58.8% |
| 2021 Q3 | 1.78 Billion JPY | 8.52% |
| 2021 Q2 | 1.64 Billion JPY | 152.49% |
| 2021 FY | 4.81 Billion JPY | 1472.33% |
| 2021 Q1 | 651.44 Million JPY | 36.15% |
| 2020 Q4 | 478.47 Million JPY | 710.42% |
| 2020 Q3 | -78.38 Million JPY | 13.1% |
| 2020 Q2 | -90.2 Million JPY | -2448.91% |
| 2020 Q1 | -3.53 Million JPY | -100.77% |
| 2020 FY | 306.34 Million JPY | -64.96% |
| 2019 Q2 | 41.91 Million JPY | -84.57% |
| 2019 FY | 874.34 Million JPY | -4.88% |
| 2019 Q4 | 457.85 Million JPY | 345.21% |
| 2019 Q3 | 102.84 Million JPY | 145.36% |
| 2019 Q1 | 271.73 Million JPY | -32.08% |
| 2018 FY | 919.2 Million JPY | 39.26% |
| 2018 Q3 | 81.24 Million JPY | 135.8% |
| 2018 Q1 | 403.41 Million JPY | -3.43% |
| 2018 Q2 | 34.45 Million JPY | -91.46% |
| 2018 Q4 | 400.09 Million JPY | 392.45% |
| 2017 Q3 | 20.32 Million JPY | 44.48% |
| 2017 FY | 660.04 Million JPY | 67.01% |
| 2017 Q1 | 207.92 Million JPY | -41.61% |
| 2017 Q4 | 417.73 Million JPY | 1955.16% |
| 2017 Q2 | 14.06 Million JPY | -93.23% |
| 2016 Q3 | -59.56 Million JPY | -109.01% |
| 2016 Q4 | 356.12 Million JPY | 697.87% |
| 2016 Q1 | 127.14 Million JPY | -41.27% |
| 2016 FY | 395.2 Million JPY | 53.42% |
| 2016 Q2 | -28.49 Million JPY | -122.41% |
| 2015 FY | 257.6 Million JPY | -18.81% |
| 2015 Q4 | 216.5 Million JPY | 0.0% |
| 2014 FY | 317.29 Million JPY | 128.27% |
| 2013 FY | 139 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | -17.761% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 97.38% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 101.198% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 97.671% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | -3363.908% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 85.4% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 52.969% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 91.1% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | -441.498% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 72.981% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 16.995% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | -174.091% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | 2196.799% |
| Tsumura & Co. | 16.7 Billion JPY | 77.409% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 66.181% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 8.37% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 76.663% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | -9.876% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 51.182% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 29.082% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 177.12% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | -14.544% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 292.287% |
| MedRx Co., Ltd | -932 Million JPY | 504.961% |
| Solasia Pharma K.K. | -1.11 Billion JPY | 439.41% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 257.798% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 49.977% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 72.441% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | 740.558% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 81.729% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | -28.099% |